GlassScriptPhysician profile
Christopher Bowlin
NPI 1922311547
$4,972.65
in general payments reported to CMS, 2019-2025
33 companies · $391 in 2025
The $391 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,125 · 2020: $689 · 2021: $471 · 2022: $611 · 2023: $948 · 2024: $738 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,076.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $1,915.93 | 2019-2025 | Grafix Pl, Stravix Pl, Collagenase Santyl |
| Trimed, INC. | $902.06 | 2019-2020 | |
| Convatec INC. | $411.43 | 2023-2024 | |
| Musculoskeletal Transplant Foundation INC. | $288.47 | 2020 | |
| Abbott Laboratories | $230.79 | 2021-2024 | Freestyle Libre 3, Eterna |
| Paragon 28, INC. | $147.19 | 2022 | |
| Kci USA, INC. | $108.91 | 2019-2023 | Activ.A.C. |
| Organogenesis INC. | $92.37 | 2020-2023 | Puraply |
| Biowound Solutions, INC. | $87.01 | 2025 | Bio-Connekt |
| Horizon Therapeutics Plc | $75.20 | 2019-2023 | Krystexxa |
| Stryker Corporation | $72.32 | 2019 | |
| Medtronic, INC. | $66.82 | 2021-2023 | Intellis Adaptivestim |
| Osiris Therapeutics INC. | $66.67 | 2019 | |
| Paratek Pharmaceuticals, INC. | $53.68 | 2022-2025 | Nuzyra |
| Kerecis Limited | $51.30 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hartmann USA, INC. | $41.90 | 2020-2025 | Zetuvit Plus 10x10 P10 |
| Glaxosmithkline, LLC. | $37.62 | 2019-2023 | Trelegy Ellipta |
| Reprise Biomedical, INC. | $36.26 | 2024-2025 | Miro3d |
| Nevro Corp. | $29.88 | 2022-2023 | Senza |
| Urgo Medical North America, LLC | $28.45 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgok2 |
| Novo Nordisk INC | $23.66 | 2019-2020 | |
| Integra Lifesciences Corporation | $21.89 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Dexcom, INC. | $21.77 | 2022 | |
| Royal Biologics, INC. | $21.55 | 2024 | |
| Xeris Pharmaceuticals, INC. | $20.80 | 2021 | |
| Medartis INC. | $18.24 | 2019 | |
| Merck Sharp & Dohme LLC | $17.36 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.41 | 2022 | |
| Medtronic Vascular, INC. | $16.12 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.99 | 2021 | |
| Medtronic USA, INC. | $13.64 | 2019 | |
| Medtronic Minimed, INC. | $11.03 | 2020 | |
| Advanced Oxygen Therapy INC. | $10.93 | 2025 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bowlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.